Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.069 | 0.7 |
mRNA | selumetinib:piperlongumine (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | T0901317 | GDSC1000 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.021 | 0.7 |
mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.7 |
mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.025 | 0.7 |
mRNA | etoposide | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
mRNA | BMS-536924 | GDSC1000 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | JNK-9L | GDSC1000 | pan-cancer | AAC | -0.015 | 0.7 |